Drugs Made In America Acquisition Corp. entered into an Amended and Restated Definitive Merger Agreement with Power Analytics Global Corp., fixing the transaction's closing valuation at $2,850,000,000. The deal structures a domestication of the SPAC to Delaware followed by a merger where PAGC survives as a wholly-owned subsidiary. Consideration consists of up to 265,116,279 new shares based on a reference price of at least $10.75. A key condition is PAGC's prior acquisition of APQC Inc., including its UltraSolar intellectual property. The transaction requires shareholder approval and the delivery of a fairness opinion from Newbridge Securities Corporation. Drugs Made In America Acquisition Corp. operates as a blank check company seeking to combine with a target in the artificial intelligence, advanced analytics, and quantum-resistant security solutions industry.

Drugs Made In America Acquisition Corp. approved a third amendment to its merger agreement with Power Analytics Global Corp. Key changes include the former sponsor forfeiting at least 50% of founder shares and surrendering 430,000 private placement rights. The company will initiate a cash tender offer for publicly held rights at $0.25 to $0.35 per right, or an exchange offer or consent solicitation. The amendment also establishes a target minimum cash of $30 million and a floor of $15 million, and introduces a potential three-party business combination contingent on a letter of intent by September 30, 2026. This is a special purpose acquisition company (SPAC) operating in the healthcare and technology sectors.